Asia Pacific Expected to Highest Growth for Osteoporosis Drugs Market by 2022

Rising geriatric population, changing lifestyle impinging bone health, and increasing prevalence of osteoporosis in post-menopausal women are some of the factors driving the growth of the global osteoporosis drugs market. In addition, increasing awareness about osteoporosis care and growing investments in R&D for the discovery of innovative drugs are also fueling the growth of the market.

 

Albany, NY -- (SBWIRE) -- 01/22/2016 -- The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market.

Complete Report with TOC @ http://www.mrrse.com/osteoporosis-drugs-market

The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs.

Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period.

North America is the largest market for osteoporosis drugs due to increasing geriatric population, growing investment in R&D for the discovery of innovative drugs, and rising prevalence of lifestyle-associated diseases in the region. Asia-Pacific is expected to exhibit high growth rates over the following five years in the global osteoporosis drugs market. China and India are expected to be the fastest-growing markets for osteoporosis drugs in Asia Pacific. Some of the key driving forces for the osteoporosis drugs market in emerging countries are rising geriatric population, a large pool of patients, changing lifestyles, increasing healthcare expenditure, and growing awareness about osteoporosis care in these regions.

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/388

Rising geriatric population, changing lifestyle impinging bone health, and increasing prevalence of osteoporosis in post-menopausal women are some of the factors driving the growth of the global osteoporosis drugs market. In addition, increasing awareness about osteoporosis care and growing investments in R&D for the discovery of innovative drugs are also fueling the growth of the market. On the other hand, side effects and complications such as irritable bowel syndrome, nausea, and ulcers in stomach or esophagus, associated with osteoporosis drugs and patent expiration of osteoporosis drugs are inhibiting growth of the global osteoporosis drugs market.

About MRRSE
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.